Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2008.16.2578 on October 27 2008

Journal of Clinical Oncology, Vol 26, No 34 (December 1), 2008: pp. 5544-5552
© 2008 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Erratum (v27,p1923)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Di Leo, A.
Right arrow Articles by Press, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Di Leo, A.
Right arrow Articles by Press, M. F.
Related Articles
Right arrowRelated Correspondence
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer

Angelo Di Leo, Henry L. Gomez, Zeba Aziz, Zanete Zvirbule, Jose Bines, Michael C. Arbushites, Stephanie F. Guerrera, Maria Koehler, Cristina Oliva, Steven H. Stein, Lisa S. Williams, Judy Dering, Richard S. Finn, Michael F. Press

From the "Sandro Pitigliani" Medical Oncology Unit, Prato, Italy; Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru; Allama Iqbal Medical College, Lahore, Pakistan; Riga Eastern University Hospital Latvian Oncology Centre, Riga, Latvia; National Cancer Institute, Rio De Janeiro, Brazil; Medicine Development Center Oncology, GlaxoSmithKline, Collegeville, PA; Geffen School of Medicine at University of California, Los Angeles; and Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA

Corresponding author: Angelo Di Leo, MD, "Sandro Pitigliani" Medical Oncology Unit, Hospital of Prato, Istituto Toscano Tumori, Prato, Italy 59100; e-mail: adileo{at}usl4.toscana.it

Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human epidermal growth factor receptor 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy of lapatinib in HER-2–negative and HER-2–uncharacterized MBC.

Patients and Methods Women with MBC were randomly assigned to first-line therapy with paclitaxel 175 mg/m2 every 3 weeks plus lapatinib 1,500 mg/d or placebo. A preplanned retrospective evaluation of HER-2 status was performed using fluorescence in situ hybridization and immunohistochemistry. The primary end point was time to progression (TTP); secondary end points were objective response rate (ORR), clinical benefit rate (CBR), event-free survival (EFS), and overall survival (OS).

Results In the intent-to-treat population (n = 579), there were no significant differences in TTP, EFS, or OS between treatment arms, although differences in ORR and CBR were noted. In 86 HER-2–positive patients (15%), treatment with paclitaxel-lapatinib resulted in statistically significant improvements in TTP, EFS, ORR, and CBR compared with paclitaxel-placebo. No differences between treatment groups were observed for any end point in HER-2–negative patients. The most common adverse events were alopecia, rash, and diarrhea. The incidence of diarrhea and rash was significantly higher in the paclitaxel-lapatinib arm. The rate of cardiac events was low, and no difference was observed between treatment arms.

Conclusion Patients with HER-2–negative or HER-2–untested MBC did not benefit from the addition of lapatinib to paclitaxel. However, first-line therapy with paclitaxel-lapatinib significantly improved clinical outcomes in HER-2–positive patients. Prospective evaluation of the efficacy and safety of this combination is ongoing in early and metastatic HER-2–positive breast cancer patients.

published online ahead of print at www.jco.org on October 27, 2008.

Supported by GlaxoSmithKline. R.S.F. is a recipient of a National Institutes of Health Loan Repayment Program award.

Presented in part at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?

Related Correspondence

  • Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?
    Eitan Amir, Bostjan Seruga, Orit Freedman, and Ian Tannock
    JCO 2009 27: 1919 [Full Text]


This article has been cited by other articles:


Home page
Mayo Clin Proc.Home page
A. Moreno-Aspitia and E. A. Perez
Treatment Options for Breast Cancer Resistant to Anthracycline and Taxane
Mayo Clin. Proc., June 1, 2009; 84(6): 533 - 545.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. Amir, B. Seruga, O. Freedman, and I. Tannock
Lapatinib Plus Paclitaxel As First-Line Therapy for Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: Inappropriate Conclusions From a Company-Sponsored Study?
J. Clin. Oncol., April 10, 2009; 27(11): 1919 - 1919.
[Full Text] [PDF]


Home page
JCOHome page
A. Di Leo, R. S. Finn, and M. F. Press
In Reply
J. Clin. Oncol., April 10, 2009; 27(11): 1920 - 1921.
[Full Text] [PDF]


Home page
JCOHome page
G. Sauter, J. Lee, J. M.S. Bartlett, D. J. Slamon, and M. F. Press
Guidelines for Human Epidermal Growth Factor Receptor 2 Testing: Biologic and Methodologic Considerations
J. Clin. Oncol., March 10, 2009; 27(8): 1323 - 1333.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2008 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online